Subscribe

AnteoTech Limited (ADO.AX)

AUD0.03 +0.00 (+0.00%)
AU ASX Healthcare Medical - Specialties
Address Brisbane Technology Park 4113
Eight Mile Plains, QLD, AU
CEO Merrill Gray
Website anteotech.com
IPO 2000-04-06
ISIN AU000000ADO8

Explore sections of this company profile

Description

AnteoTech Limited develops, manufactures, commercializes, and distributes products for clean energy technology and life science markets primarily in Australia, Asia, Europe, and North America. The company’s products include AnteoBind, a metal-ion complex-based activation technology that offers an alternative to conventionally used chemistries for the life sciences industry; AnteoBind NXT solution for the development of diagnostic tests; AnteoBind Micro and Micro Kit, a micro-particle-based assay development and bioseparation; AnteoBind Sub-Micron, Particle-based assay development, and bioseparation; AnteoBind Biosensor, a planar solid phase assay development; Activation Kit Multiplex Microspheres, an immunoassay development; and Nano Kit, a nanoparticle-based lateral flow assay development and bioseparation. It also provides AnteoX, an additive that reinforces battery binders that enhance performance of silicon containing anodes; and Ultranode, an ultra-high silicon anode design to offer high performance for lithium-ion batteries. In addition, the company offers contract services. The company was formerly known as Anteo Diagnostics Limited and changed its name to AnteoTech Limited in November 2019. AnteoTech Limited is headquartered in Eight Mile Plains, Australia.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
AUD0.03 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
18M
Beta
1.10
Float Shares
2.44B
Free Float %
82.1%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-13.64% +100.00% +280.00% +216.67% +105.41% +72.73% +375.00% -15.56% -88.13% -9.75% -98.46%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.03
Ratings Trend (MoM)
Rating 2026-05 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-19.48
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Specialties: +8.3%
    +110.4% ★ Q4'25: -74.5% (vs Q4'23)
  • ✗
    EPS growth Medical - Specialties: +10.1%
    +35.0% ★ Q4'25: +145.5% (vs Q4'23)
  • ✗
    FCF margin FCF growth · Medical - Specialties: +51.3%
    -686.4% Q4'25: -595.8% (vs Q4'23)
  • ✗
    EBIT margin Medical - Specialties: +12.6%
    -937.2% Q4'25: -4,147.5% (vs Q4'23)
  • ✗
    ROIC Medical - Specialties: +6.6%
    -327.9% Q4'25: -280.1% (vs Q4'23)
  • ✗
    Share dilution Medical - Specialties: 0.0%
    +16.8% Q4'25: +26.4% (vs Q4'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×
    -0.25× Q4'25: -0.21× (vs Q4'23)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.57) × ERP
WACC = 98% × Ke + 2% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 0.03
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Jun 2001
actual 		Jun 2021
actual 		Jun 2022
actual 		Jun 2023
actual 		Jun 2024
actual 		Jun 2025
actual 		Jun 2026
1 Rev. Ana.
1 EPS Ana. 		Jun 2027
1 Rev. Ana.
1 EPS Ana. 		Jun 2028
1 Rev. Ana.
1 EPS Ana. 		Jun 2029
1 Rev. Ana. 		Jun 2030
1 Rev. Ana.
Revenue
—
est: 60.9K (-100.0%)
898.1K
est: 1.40M (-35.9%)
760.9K
est: 48.70M (-98.4%)
365.7K
est: 132.50M (-99.7%)
460.4K
est: 209.00M (-99.8%)
968.9K
est: 232.50M (-99.6%)
900.0K
900.0K – 900.0K
-99.6% YoY
2.80M
2.80M – 2.80M
+211.1% YoY
4.20M
4.20M – 4.20M
+50.0% YoY
8.30M
8.30M – 8.30M
+97.6% YoY
15.40M
15.40M – 15.40M
+85.5% YoY
EBITDA
-1.39M
est: -60.9K (-2,187.4%)
-7.18M
est: -1.40M (-412.9%)
-12.07M
est: -48.70M (+75.2%)
-12.35M
est: -132.50M (+90.7%)
-11.57M
est: -209.00M (+94.5%)
-7.96M
est: -232.50M (+96.6%)
-900.0K
-900.0K – -900.0K
+99.6% YoY
-2.80M
-2.80M – -2.80M
-211.1% YoY
-4.20M
-4.20M – -4.20M
-50.0% YoY
-8.30M
-8.30M – -8.30M
-97.6% YoY
-15.40M
-15.40M – -15.40M
-85.5% YoY
EBIT
—
est: -60.9K (+100.0%)
-8.17M
est: -1.40M (-483.7%)
-10.72M
est: -48.70M (+78.0%)
-15.85M
est: -132.50M (+88.0%)
-12.61M
est: -209.00M (+94.0%)
-9.08M
est: -232.50M (+96.1%)
-900.0K
-900.0K – -900.0K
+99.6% YoY
-2.80M
-2.80M – -2.80M
-211.1% YoY
-4.20M
-4.20M – -4.20M
-50.0% YoY
-8.30M
-8.30M – -8.30M
-97.6% YoY
-15.40M
-15.40M – -15.40M
-85.5% YoY
Net Income
-1.40M
est: -266.69M (+99.5%)
-6.22M
-10.72M
-12.65M
est: 25.92M (-148.8%)
-8.88M
est: 77.76M (-111.4%)
-6.76M
est: 103.68M (-106.5%)
-26.14M
-26.14M – -26.14M
-125.2% YoY
—
— – —
+100.0% YoY
—
— – —
—
— – —
—
— – —
SGA
—
est: 674.1K (-100.0%)
4.70M
est: 15.50M (-69.6%)
7.73M
est: 539.07M (-98.6%)
6.88M
est: 1.47B (-99.5%)
5.92M
est: 2.31B (-99.7%)
8.03M
est: 2.57B (-99.7%)
9.96M
9.96M – 9.96M
-99.6% YoY
30.99M
30.99M – 30.99M
+211.1% YoY
46.49M
46.49M – 46.49M
+50.0% YoY
91.87M
91.87M – 91.87M
+97.6% YoY
170.47M
170.47M – 170.47M
+85.5% YoY
EPS
-0.11
est: -0.10 (-7.8%)
0.00
-0.01
-0.01
est: 0.01 (-163.5%)
0.00
est: 0.03 (-113.4%)
0.00
est: 0.04 (-106.6%)
-0.01
-0.01 – -0.01
-125.2% YoY
—
— – —
+100.0% YoY
—
— – —
—
— – —
—
— – —
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-28 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-27 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-26 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-25 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-19 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-18 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-15 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-14 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-13 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-12 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-11 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-08 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-07 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-06 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-05 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-04 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-01 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-30 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-29 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-28 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-27 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-24 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-23 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-17 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-16 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-20.90M
OE per share TTM
-0.01
Owner's Yield
-20.33%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
416.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-405.00
Shares Outstanding
2.97B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Merrill Christina Gray AFAIM MD, Chief Executive Officer & Director 227.6K female
Andrew Scott Victor Waddell AGIA FCPA Interim CFO & Company Secretary — male
Friederike Graser Director of Strategic Growth Initiatives — female
Manuel Wieser Chief Technology Officer — male
Selahattin Guldu Executive Vice President of Commercial Banking — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Specialties